Name
*
First Name
Last Name
Email
*
example@example.com
Degree(s)
*
1. Which of the following statements best describes the state of fluid biomarkers in MS?
*
a. Elevated serum NfL is diagnostic of MS
b. CSF Tau is promising in progressive MS
c. NfL and GFAP are promising biomarkers in MS but are non-specific for the disease process
d. Well validated proteomics panels can now be used with confidence for clinical decision making in MS
2. Which of the following statements about CAR-T therapy is not true?
*
a. CAR-T cells need to be administered intrathecally to enter the CNS.
b. Transplantation is preceded by a short course of lymphodepleting chemotherapy.
c. Transplantation sometimes is complicated by neurologic adverse effects.
d. The technology is rapidly evolving
e. CAR-T transplantation is being tested in both relapsing and progressive MS.
3. The phase II EMBOLD trial failed. What did it test?
*
a. Enriched antibodies to EBV
b. Tenofovir/emtricitabine
c. Allogenic EBV-specific T cells
d. Autologous EBV-specific T cells
4. Which of the following types of machine learning models underlies generative artificial intelligence, like ChatGPT?
*
a. Perceptrons
b. Large language models
c. Tokens
d. Decision trees
5. Which of the following MS diagnostic imaging markers requires susceptibility-sensitive MRI?
*
a. Dissemination in space
b. Dissemination in time
c. Central vein sign
d. Optic neuritis
6. Which of the following Anti-CD20 mAbs is a glycoengineered chimeric mAb?
*
a. Rituximab
b. Ofatumumab
c. Ocrelizumab
d. Ublituximab
7. Tolebrutinib, a brain penetrant BTK inhibitor, was shown to delay the onset of disability progression in patients with:
*
a. Relapsing multiple sclerosis
b. Non-relapsing secondary progressive multiple sclerosis
c. Primary progressive multiple sclerosis
d. Radiologically isolated syndrome
Submit
Should be Empty: